just told!! Exercise your warrants (by sending
$5.00 X 1700 to Alkermes with the exercise form) and
you will get your stock which is worth today about
$207,000.00! If you don't have the form, call ALKS. You hit it
pretty good. I'm only in for 1/2 unit, but I'm up on the
warrant exercise by $97,000.00. Not bad for waiting.
Cereport is far from dead, I believe.
I am a limited partner, and can tell you only
that Stage II tests are still in progress with
RMP_7(now Cereport) after terminating the first attempt
with carboplatin in 1999. I think with all the
successes Alkermes is now having with their other products,
RMP-7 development has been slowed. You should be able
to get more information at the web site
www.alkermes.com. Click on news releases and then April 7,
The partnership was formed to only develop products
derived from RMP type compounds, with the warrants
included in the offering as a "sweetener". If your father
invested $50,000 in the partnership he should have
received 1700 shares of a new class A warrant exercisable
at $5.00 per share through March 31, 2000, provided
he agreed to the exchange in November 1994. If he
has not yet exercised these, their current value
should be $175,000. Not bad...
Okay. I just looked through paperwork and
discovered I'm a Class A Limited Partner of Alkermes. Is
this interest in Cereport alone? And I just can't
believe Cereport's all over with. No chance of royalties.
Wondering if I'm entitled to anything but these warrants,
the last one expiring 3/31/00. My father had invested
$50,000 in the LP - the warrants did not bring in
$50,000. Any input would be greatly appreciated,
especially if anyone out there is also a Class A Limited
Cereport (lobradimil), formerly
RMP-7, is Alkermes' proprietary agent for facilitating
drug delivery to the brain.
designed to facilitate the delivery of pharmaceutical
compounds to the brain by transiently increasing the
permeability of the blood-brain barrier. The blood-brain
barrier is comprised of microvessels whose structure
limits the diffusion of substances between cells and
thus limits permeation into the brain. In essence, the
endothelial cells of the brain's capillaries form tight
junctions that constitute the blood-brain barrier.
Cereport is a bradykinin agonist which temporarily
increases the permeability of the blood-brain barrier by
activating B2 receptors on these endothelial cells. The
ability to transiently open the junctions between the
tightly joined endothelial cells allows for the selective
transport of drug molecules across the blood-brain barrier
into the brain.
Cereport is currently being
evaluated in combination with the chemotherapeutic agent
carboplatin in patients with malignant brain tumors and brain
metastases. Cereport's safety, tolerability in combination
with other drugs and preliminary efficacy have been
tested in a series of clinical trials in more than 600
human subjects. Alkermes has completed four Phase II
clinical trials of Cereport and carboplatin in patients
with recurrent, malignant brain tumors.
October, 1997, Alkermes announced a collaboration with
ALZA Corporation relating to the development and
commercialization of Cereport.
anyone in on original partnership if so what is
the latest info on royalities i talked to Pops couple
years ago he related we should start to receive in 2000
/ 2001 we all of the deals going on I am totally
confused. I hope board is considering stock split. I have
been since get go not getting out now just starting to
put icing on cake.